ATE310016T1 - Fusionsprotein regulatorischer/akzessorischer hiv-proteine - Google Patents
Fusionsprotein regulatorischer/akzessorischer hiv-proteineInfo
- Publication number
- ATE310016T1 ATE310016T1 AT03730029T AT03730029T ATE310016T1 AT E310016 T1 ATE310016 T1 AT E310016T1 AT 03730029 T AT03730029 T AT 03730029T AT 03730029 T AT03730029 T AT 03730029T AT E310016 T1 ATE310016 T1 AT E310016T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- fusion protein
- nucleic acids
- regulatory
- hiv proteins
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 230000001105 regulatory effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200200754 | 2002-05-16 | ||
PCT/EP2003/005039 WO2003097675A1 (en) | 2002-05-16 | 2003-05-14 | Fusion protein of hiv regulatory/accessory proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE310016T1 true ATE310016T1 (de) | 2005-12-15 |
Family
ID=29433046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03730029T ATE310016T1 (de) | 2002-05-16 | 2003-05-14 | Fusionsprotein regulatorischer/akzessorischer hiv-proteine |
AT05017695T ATE407143T1 (de) | 2002-05-16 | 2003-05-14 | Fusionsprotein des regulatorische/akzessorische hiv proteine |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05017695T ATE407143T1 (de) | 2002-05-16 | 2003-05-14 | Fusionsprotein des regulatorische/akzessorische hiv proteine |
Country Status (24)
Country | Link |
---|---|
US (7) | US20050222388A1 (de) |
EP (2) | EP1506223B1 (de) |
JP (3) | JP2006502704A (de) |
KR (4) | KR101196178B1 (de) |
CN (3) | CN101108882A (de) |
AT (2) | ATE310016T1 (de) |
AU (2) | AU2003240638B2 (de) |
BR (1) | BR0309963A (de) |
CA (1) | CA2483640A1 (de) |
CY (1) | CY1108638T1 (de) |
DE (2) | DE60302356T2 (de) |
DK (2) | DK1652857T3 (de) |
EA (1) | EA007154B1 (de) |
ES (2) | ES2313166T3 (de) |
HK (1) | HK1076822A1 (de) |
IL (3) | IL164178A0 (de) |
MX (1) | MXPA04010683A (de) |
NO (1) | NO20045229L (de) |
NZ (2) | NZ536499A (de) |
PL (2) | PL397252A1 (de) |
PT (1) | PT1652857E (de) |
SI (2) | SI1506223T1 (de) |
UA (3) | UA92788C2 (de) |
WO (1) | WO2003097675A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
NZ536499A (en) | 2002-05-16 | 2008-04-30 | Bavarian Nordic As | Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini |
ATE520708T1 (de) | 2003-03-28 | 2011-09-15 | Us Gov Health & Human Serv | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung |
IL286053B2 (en) * | 2005-10-18 | 2023-03-01 | Nat Jewish Health | A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin |
AU2007345768B2 (en) * | 2006-07-27 | 2013-08-01 | Ligocyte Pharmaceuticals, Inc. | Chimeric influenza virus-like particles |
EP2044224A4 (de) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | Chimärische virusähnliche partikel |
KR20170078862A (ko) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
CA2731767C (en) | 2008-07-21 | 2016-12-06 | Taiga Biotechnologies, Inc. | Differentiated anucleated cells and method for preparing the same |
EP3916010A1 (de) | 2008-08-28 | 2021-12-01 | Taiga Biotechnologies, Inc. | Modulatoren von myc, verfahren zur verwendung davon und verfahren zur identifizierung von mitteln zur modulierung von myc |
CA2767924A1 (en) * | 2009-10-08 | 2011-04-14 | Bavarian Nordic A/S | Generation of a broad t-cell response in humans against hiv |
US9358281B2 (en) * | 2009-10-09 | 2016-06-07 | New York University | Methods, agents and peptides for inducing an innate immune response in HIV vaccination |
CN102753582A (zh) | 2009-11-03 | 2012-10-24 | 莱戈赛特医药股份有限公司 | 嵌合RSV-F多肽、和慢病毒或α-反转录病毒GAG基VLP |
EP2620446A1 (de) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogene zur HIV-Impfung |
EP3868387A1 (de) | 2012-07-20 | 2021-08-25 | Taiga Biotechnologies, Inc. | Verbesserte wiederherstellung und autorenkonstitution des hämatopoietischen abteils |
US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
WO2015192339A1 (zh) * | 2014-06-18 | 2015-12-23 | 中山大学 | 一种嵌合载体及其制备方法和应用 |
CN104130331B (zh) * | 2014-06-19 | 2017-06-06 | 中山大学 | 一种抗hiv‑1病毒药物及其制备和应用 |
FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
CN105330729A (zh) * | 2015-11-18 | 2016-02-17 | 南京医科大学 | 一种人类免疫缺陷病毒Vpr蛋白的制备方法 |
CN113786476A (zh) | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
CN116322757A (zh) | 2019-11-14 | 2023-06-23 | 埃利克斯疗法公司 | 用于疫苗的剂量方案 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0942747A1 (de) * | 1996-08-26 | 1999-09-22 | Chiron Corporation | Impfungstherapie nach einer hiv-infektion |
GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
FR2773156B1 (fr) * | 1997-12-26 | 2000-03-31 | Biovacs Inc | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida |
FI105105B (fi) | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CN1326873C (zh) | 2000-01-31 | 2007-07-18 | 史密丝克莱恩比彻姆生物有限公司 | 用于hiv预防或治疗性免疫的疫苗 |
WO2001092470A2 (en) * | 2000-03-02 | 2001-12-06 | Emory University | Dna expression vectors and methods of use |
US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
AU8349301A (en) * | 2000-07-14 | 2002-01-30 | Univ Pennsylvania | Dna vaccines encoding hiv accessory proteins |
AU2872202A (en) * | 2000-11-01 | 2002-05-15 | Us Gov Health & Human Serv | Expression vectors able to elicit improved immune response and methods of using same |
US7628980B2 (en) * | 2000-11-23 | 2009-12-08 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
NZ536499A (en) * | 2002-05-16 | 2008-04-30 | Bavarian Nordic As | Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini |
-
2003
- 2003-05-14 NZ NZ536499A patent/NZ536499A/en not_active IP Right Cessation
- 2003-05-14 JP JP2004506348A patent/JP2006502704A/ja active Pending
- 2003-05-14 NZ NZ556144A patent/NZ556144A/en not_active IP Right Cessation
- 2003-05-14 CA CA002483640A patent/CA2483640A1/en not_active Abandoned
- 2003-05-14 KR KR1020117017944A patent/KR101196178B1/ko not_active IP Right Cessation
- 2003-05-14 ES ES05017695T patent/ES2313166T3/es not_active Expired - Lifetime
- 2003-05-14 CN CNA2007101039526A patent/CN101108882A/zh active Pending
- 2003-05-14 EA EA200401504A patent/EA007154B1/ru not_active IP Right Cessation
- 2003-05-14 PL PL397252A patent/PL397252A1/pl not_active Application Discontinuation
- 2003-05-14 DK DK05017695T patent/DK1652857T3/da active
- 2003-05-14 MX MXPA04010683A patent/MXPA04010683A/es active IP Right Grant
- 2003-05-14 IL IL16417803A patent/IL164178A0/xx active IP Right Grant
- 2003-05-14 UA UAA200811374A patent/UA92788C2/ru unknown
- 2003-05-14 PT PT05017695T patent/PT1652857E/pt unknown
- 2003-05-14 UA UA20041109408A patent/UA85373C2/ru unknown
- 2003-05-14 US US10/514,740 patent/US20050222388A1/en not_active Abandoned
- 2003-05-14 UA UA20041109410A patent/UA82998C2/ru unknown
- 2003-05-14 DE DE60302356T patent/DE60302356T2/de not_active Expired - Lifetime
- 2003-05-14 DK DK03730029T patent/DK1506223T3/da active
- 2003-05-14 SI SI200330168T patent/SI1506223T1/sl unknown
- 2003-05-14 DE DE60323407T patent/DE60323407D1/de not_active Expired - Lifetime
- 2003-05-14 CN CNA200710000639XA patent/CN1982332A/zh active Pending
- 2003-05-14 EP EP03730029A patent/EP1506223B1/de not_active Expired - Lifetime
- 2003-05-14 KR KR1020047017968A patent/KR100996330B1/ko not_active IP Right Cessation
- 2003-05-14 ES ES03730029T patent/ES2253675T3/es not_active Expired - Lifetime
- 2003-05-14 EP EP05017695A patent/EP1652857B9/de not_active Expired - Lifetime
- 2003-05-14 AT AT03730029T patent/ATE310016T1/de active
- 2003-05-14 WO PCT/EP2003/005039 patent/WO2003097675A1/en active Application Filing
- 2003-05-14 KR KR1020107008995A patent/KR20100063126A/ko not_active Application Discontinuation
- 2003-05-14 CN CNB038111195A patent/CN1325512C/zh not_active Expired - Fee Related
- 2003-05-14 SI SI200331443T patent/SI1652857T1/sl unknown
- 2003-05-14 AT AT05017695T patent/ATE407143T1/de active
- 2003-05-14 BR BR0309963-6A patent/BR0309963A/pt not_active IP Right Cessation
- 2003-05-14 AU AU2003240638A patent/AU2003240638B2/en not_active Ceased
- 2003-05-14 PL PL03372092A patent/PL372092A1/xx not_active IP Right Cessation
- 2003-05-14 KR KR1020127021229A patent/KR20120106894A/ko not_active Application Discontinuation
-
2004
- 2004-09-21 IL IL164178A patent/IL164178A/en not_active IP Right Cessation
- 2004-11-29 NO NO20045229A patent/NO20045229L/no not_active Application Discontinuation
-
2005
- 2005-09-30 HK HK05108707A patent/HK1076822A1/xx not_active IP Right Cessation
-
2006
- 2006-07-18 US US11/488,803 patent/US7569228B2/en not_active Expired - Fee Related
-
2008
- 2008-12-03 CY CY20081101401T patent/CY1108638T1/el unknown
- 2008-12-04 AU AU2008252074A patent/AU2008252074B2/en not_active Ceased
-
2009
- 2009-02-26 IL IL197304A patent/IL197304A0/en unknown
- 2009-05-11 JP JP2009114359A patent/JP2009178165A/ja active Pending
- 2009-06-24 US US12/490,424 patent/US8143054B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,164 patent/US8147839B2/en not_active Expired - Fee Related
- 2009-11-03 US US12/611,188 patent/US8137931B2/en not_active Expired - Fee Related
- 2009-12-22 JP JP2009290256A patent/JP2010099084A/ja active Pending
-
2012
- 2012-02-14 US US13/372,723 patent/US8435535B2/en not_active Expired - Fee Related
- 2012-02-14 US US13/372,706 patent/US8389275B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108638T1 (el) | Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων | |
IL264925A (en) | Isolated or recombinant proteins that induce an immune response against S. PYOGENES, preparations containing them and their uses | |
DE60238472D1 (de) | Abschwächung der immunogenizität von fusionsproteinen | |
CY1113379T1 (el) | Πεπτιδια κdr και εμβολια που τα περιλαμβανουν | |
DK2327719T3 (da) | Hybrid- og tandemekspression af neisseria-proteiner | |
ECSP093601A (es) | Proteínas derivadas del virus del síndrome de mancha blanca y sus usos | |
DE69938302D1 (de) | Neisseria meningitidis antigene und zusammenstellungen | |
MX9200709A (es) | Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas. | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
DK1530637T3 (da) | Carlsberg-subtilisin-proteiner med nedsat immunogenitet | |
DE60335726D1 (de) | Chromoprotein und fluoroproteine | |
PE20231439A1 (es) | Proteinas f de hmpv estabilizadas por prefusion | |
ATE469170T1 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
DK1417222T3 (da) | Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop | |
CO5650177A2 (es) | Constructos geneticos y composiciones que comprenden rre y cte y usos de estos | |
WO2003029285A3 (en) | Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections | |
WO2001049712A3 (en) | Vaccine against isav (infectious salmon anaemia virus) | |
AU2003281917A8 (en) | Vaccine against infections caused by oncoviruses such as the feline leucosis virus of cats | |
NO179010C (no) | Antistoffer mot höyt konserverte aminosyresekvenser fra immunogene forbindelser og anvendelse derav i immunoanalyser | |
CY1113749T1 (el) | Συνθεσεις εμβολιων dna και μεθοδοι χρησης τους |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1506223 Country of ref document: EP |